Literature DB >> 12776182

The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases.

Anne Devin1, Yong Lin, Zheng-gang Liu.   

Abstract

The death-domain kinase RIP (receptor-interacting protein) is an important effector of tumour necrosis factor (TNF) signalling and is essential for TNF-induced nuclear factor-kappaB activation. However, the function of RIP in the TNF-induced activation of mitogen-activated protein kinases (MAPKs) has not been fully investigated. In this report, using Rip null (Rip(-/-)) mouse fibroblast cells, we investigated whether RIP is required for TNF-induced activation of the MAPKs extracellular-signal-related kinase (ERK), p38 and c-Jun amino-terminal kinase (JNK). We found that TNF-induced activation of ERK, p38 and JNK is decreased in Rip(-/-) cells. The activation of these kinases by interleukin-1 is normal in Rip(-/-) cells. More importantly, we showed that the kinase activity of RIP is needed for ERK activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776182      PMCID: PMC1319199          DOI: 10.1038/sj.embor.embor854

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  24 in total

Review 1.  Mitogen-activated protein kinase cascades as regulators of stress responses.

Authors:  M Karin
Journal:  Ann N Y Acad Sci       Date:  1998-06-30       Impact factor: 5.691

2.  Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule.

Authors:  N Holler; R Zaru; O Micheau; M Thome; A Attinger; S Valitutti; J L Bodmer; P Schneider; B Seed; J Tschopp
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

3.  MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation.

Authors:  T Yujiri; M Ware; C Widmann; R Oyer; D Russell; E Chan; Y Zaitsu; P Clarke; K Tyler; Y Oka; G R Fanger; P Henson; G L Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 4.  Tumor necrosis factor, other cytokines and disease.

Authors:  K J Tracey; A Cerami
Journal:  Annu Rev Cell Biol       Date:  1993

5.  Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain.

Authors:  V Baud; Z G Liu; B Bennett; N Suzuki; Y Xia; M Karin
Journal:  Genes Dev       Date:  1999-05-15       Impact factor: 11.361

6.  RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis.

Authors:  A T Ting; F X Pimentel-Muiños; B Seed
Journal:  EMBO J       Date:  1996-11-15       Impact factor: 11.598

7.  Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2.

Authors:  C Reinhard; B Shamoon; V Shyamala; L T Williams
Journal:  EMBO J       Date:  1997-03-03       Impact factor: 11.598

8.  The death domain kinase RIP mediates the TNF-induced NF-kappaB signal.

Authors:  M A Kelliher; S Grimm; Y Ishida; F Kuo; B Z Stanger; P Leder
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

9.  Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific.

Authors:  M Lewis; L A Tartaglia; A Lee; G L Bennett; G C Rice; G H Wong; E Y Chen; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

Review 10.  Cellular responses to tumor necrosis factor.

Authors:  Z G Liu; J Han
Journal:  Curr Issues Mol Biol       Date:  2001-10       Impact factor: 2.081

View more
  43 in total

1.  zVAD-induced necroptosis in L929 cells depends on autocrine production of TNFα mediated by the PKC-MAPKs-AP-1 pathway.

Authors:  Y-T Wu; H-L Tan; Q Huang; X-J Sun; X Zhu; H-M Shen
Journal:  Cell Death Differ       Date:  2010-06-11       Impact factor: 15.828

2.  The role of TRADD in TRAIL-induced apoptosis and signaling.

Authors:  Xiumei Cao; Yelena L Pobezinskaya; Michael J Morgan; Zheng-gang Liu
Journal:  FASEB J       Date:  2010-12-27       Impact factor: 5.191

3.  Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis.

Authors:  Zhaoyu Jin; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2006-08-28       Impact factor: 4.272

4.  Inhibition of proinflammatory and innate immune signaling pathways by a cytomegalovirus RIP1-interacting protein.

Authors:  Claudia Mack; Albert Sickmann; David Lembo; Wolfram Brune
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

Review 5.  Life and death by death receptors.

Authors:  Maria Eugenia Guicciardi; Gregory J Gores
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

6.  The MLKL Channel in Necroptosis Is an Octamer Formed by Tetramers in a Dyadic Process.

Authors:  Deli Huang; Xinru Zheng; Zi-An Wang; Xin Chen; Wan-Ting He; Yingying Zhang; Jin-Gen Xu; Hang Zhao; Wenke Shi; Xin Wang; Yongqun Zhu; Jiahuai Han
Journal:  Mol Cell Biol       Date:  2017-02-15       Impact factor: 4.272

7.  Tumour necrosis factor receptor 1 mediates endoplasmic reticulum stress-induced activation of the MAP kinase JNK.

Authors:  Qingfeng Yang; You-Sun Kim; Yong Lin; Joseph Lewis; Len Neckers; Zheng-Gang Liu
Journal:  EMBO Rep       Date:  2006-05-05       Impact factor: 8.807

8.  TRAF2 plays a key, nonredundant role in LIGHT-lymphotoxin beta receptor signaling.

Authors:  You-Sun Kim; Sergei A Nedospasov; Zheng-Gang Liu
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 9.  Tumor necrosis factor and cancer, buddies or foes?

Authors:  Xia Wang; Yong Lin
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

10.  Receptor-interacting protein shuttles between cell death and survival signaling pathways.

Authors:  Pachiyappan Kamarajan; Julius Bunek; Yong Lin; Gabriel Nunez; Yvonne L Kapila
Journal:  Mol Biol Cell       Date:  2009-12-02       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.